Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

The majority of neuroblastoma patients have tumors that initially respond to chemotherapy, but a large proportion of patients will experience therapy-resistant relapses. The molecular basis of this aggressive phenotype is unknown. Whole genome sequencing of 23 paired diagnostic and relapsed neurobla...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Nat Genet
Main Authors: Eleveld, Thomas F., Oldridge, Derek A., Bernard, Virginie, Koster, Jan, Daage, Leo Colmet, Diskin, Sharon J., Schild, Linda, Bentahar, Nadia Bessoltane, Bellini, Angela, Chicard, Mathieu, Lapouble, Eve, Combaret, Valérie, Legoix-Né, Patricia, Michon, Jean, Pugh, Trevor J., Hart, Lori S., Rader, JulieAnn, Attiyeh, Edward F., Wei, Jun S., Zhang, Shile, Naranjo, Arlene, Gastier-Foster, Julie M., Hogarty, Michael D., Asgharzadeh, Shahab, Smith, Malcolm A., Guidry Auvil, Jaime M., Watkins, Thomas B. K., Zwijnenburg, Danny A., Ebus, Marli E., van Sluis, Peter, Hakkert, Anne, van Wezel, Esther, van der Schoot, C. Ellen, Westerhout, Ellen M., Schulte, Johannes H., Tytgat, Godelieve A., Dolman, M. Emmy M., Janoueix-Lerosey, Isabelle, Gerhard, Daniela S., Caron, Huib N., Delattre, Olivier, Khan, Javed, Versteeg, Rogier, Schleiermacher, Gudrun, Molenaar, Jan J., Maris, John M.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2015
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775079/
https://ncbi.nlm.nih.gov/pubmed/26121087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ng.3333
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים